Travere Therapeutics (TVTX) Short Interest Ratio & Short Volume $44.43 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$44.44 +0.01 (+0.01%) As of 05/22/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Travere Therapeutics Short Interest OverviewAs of April 30, 2026, Travere Therapeutics (TVTX) had a short interest of 14.22 million shares sold short, representing 16.00% of the public float. This marks a 11.72% increase in short interest since the prior report. The short interest ratio (days to cover) is 7.2, meaning it would take 7.2 days of the average trading volume of 2.42 million shares to cover all short positions.Current Short Interest14,216,705 sharesPrevious Short Interest12,725,544 sharesChange Vs. Previous Month11.72%Dollar Volume Sold Short$598.81 millionShort Interest Ratio7.2 Days to CoverLast Record DateApril 30, 2026Outstanding Shares92,990,000 sharesShort Percent of Float16.00%Today's Trading Volume803,359 sharesAverage Trading Volume2,421,172 sharesToday's Volume Vs. Average33% Short Selling Travere Therapeutics? Sign up to receive the latest short interest report for Travere Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTVTX Short Interest Over TimeTVTX Days to Cover Over TimeTVTX Percentage of Float Shorted Over Time Travere Therapeutics Tesla Short Interest History & Recent Changes ExportReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202614,216,705 shares $598.81 million +11.7%16.0%7.2 $42.12 11/14/202510,355,808 shares $357.28 million -4.8%12.1%4.81 $34.50 10/31/202510,879,506 shares $382.52 million -8.1%12.7%4.98 $35.16 10/15/202511,840,000 shares $317.90 million +5.3%13.8%5.8 $26.85 9/30/202511,240,000 shares $268.64 million -8.8%N/A5.7 $23.90 9/15/202512,320,000 shares $283.48 million +2.0%N/A6.4 $23.01 8/31/202512,080,000 shares $211.40 million -0.3%14.1%6.7 $17.50 8/15/202512,110,000 shares $227.91 million +14.0%N/A8.1 $18.82 7/31/202510,620,000 shares $164.08 million -17.4%12.4%6.8 $15.45 7/15/202512,860,000 shares $210.65 million +857,233.3%N/A7.9 $16.38 Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 6/30/20251,500 shares $22.20 thousand -100.0%0.0%0 $14.80 6/15/202510,330,000 shares $149.79 million -17.4%12.1%5.9 $14.50 5/31/202512,500,000 shares $187.25 million +19.9%16.6%7.1 $14.98 5/15/202510,430,000 shares $220.59 million -2.0%13.9%5.8 $21.15 4/30/202510,640,000 shares $221.42 million -3.7%N/A5.7 $20.81 4/15/202511,050,000 shares $164.76 million -4.4%14.7%6.2 $14.91 3/31/202511,560,000 shares $207.16 million +3.3%15.4%6.6 $17.92 3/15/202511,190,000 shares $220.78 million +2.2%14.9%7 $19.73 2/28/202510,950,000 shares $234.33 million -3.1%14.6%7.2 $21.40 2/15/202511,300,000 shares $258.88 million +18.2%15.0%7.7 $22.91 1/31/20259,560,000 shares $195.60 million -0.2%N/A6.8 $20.46 1/15/20259,580,000 shares $173.11 million +9.9%N/A7.4 $18.07 12/31/20248,720,000 shares $151.90 million +17.7%N/A5.9 $17.42 12/15/20247,410,000 shares $128.34 million -2.1%N/A4.5 $17.32 11/30/20247,570,000 shares $142.39 million +8.6%N/A4.3 $18.81 11/15/20246,970,000 shares $123.51 million -12.8%N/A3.6 $17.72 10/31/20247,990,000 shares $139.83 million -1.5%N/A4.4 $17.50 10/15/20248,110,000 shares $143.47 million +16.5%N/A4.7 $17.69 9/30/20246,960,000 shares $97.37 million -19.6%N/A4.2 $13.99 9/15/20248,660,000 shares $116.74 million -6.4%N/A6.2 $13.48 8/31/20249,250,000 shares $87.60 million -0.5%N/A7.2 $9.47 8/15/20249,300,000 shares $81.65 million -7.8%N/A8.5 $8.78 7/31/202410,090,000 shares $96.26 million -0.1%N/A8.8 $9.54 7/15/202410,100,000 shares $99.08 million -2.1%N/A8.2 $9.81 6/30/202410,320,000 shares $84.83 million -23.1%N/A8.2 $8.22 6/15/202413,414,700 shares $96.18 million -0.4%N/A11 $7.17 5/31/202413,470,000 shares $99.95 million +0.2%N/A11.3 $7.42 5/15/202413,440,000 shares $91.39 million +4.9%N/A11 $6.80 4/30/202412,810,000 shares $70.84 million +8.6%N/A10.3 $5.53 4/15/202411,800,000 shares $74.58 million +11.3%N/A9.9 $6.32I was right about SpaceX (Ad)Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.See how to claim your stake in SpaceX before the public can 3/31/202410,600,000 shares $81.73 million +5.3%N/A8.8 $7.71 3/15/202410,070,000 shares $75.42 million -1.9%N/A8.2 $7.49 2/29/202410,260,000 shares $77.57 million +5.1%N/A7.5 $7.56 2/15/20249,760,000 shares $85.30 million -1.7%N/A6.7 $8.74 1/31/20249,930,000 shares $88.67 million +2.3%N/A6.3 $8.93 1/15/20249,710,000 shares $92.54 million -2.1%N/A5.8 $9.53 12/31/20239,920,000 shares $89.18 million +2.9%N/A5.9 $8.99 12/15/20239,640,000 shares $83.48 million -3.1%N/A5.8 $8.66 11/30/20239,950,000 shares $62.49 million -6.7%N/A5 $6.28 11/15/202310,660,000 shares $65.77 million +21.0%N/A5.9 $6.17 10/31/20238,810,000 shares $57.09 million +0.5%N/A5.2 $6.48 10/15/20238,770,000 shares $62.27 million +4.2%N/A5.6 $7.10 9/30/20238,420,000 shares $75.27 million -6.9%N/A5.8 $8.94 9/15/20239,040,000 shares $123.76 million +5.7%N/A6.7 $13.69 8/31/20238,550,000 shares $122.09 million +5.6%N/A8.3 $14.28 8/15/20238,100,000 shares $123.12 million +0.4%N/A7.6 $15.20 7/31/20238,070,000 shares $138.72 million -2.7%N/A7.3 $17.19 7/15/20238,290,000 shares $126.92 million -2.5%N/A6.5 $15.31 6/30/20238,500,000 shares $130.56 million +11.0%N/A6.3 $15.36 6/15/20237,660,000 shares $131.75 million +4.9%N/A5.4 $17.20 5/31/20237,300,000 shares $130.60 million -3.2%N/A5.4 $17.89 5/15/20237,540,000 shares $123.20 million -4.1%N/A4.7 $16.34 4/30/20237,860,000 shares $169.54 million -3.7%N/A4.7 $21.57 4/15/20238,160,000 shares $165.81 million -4.5%N/A5.6 $20.32 3/31/20238,540,000 shares $192.06 million +14.8%N/A5.7 $22.49 3/15/20237,440,000 shares $158.25 million -1.6%N/A5.4 $21.27 2/28/20237,560,000 shares $167.53 million +9.9%N/A5.7 $22.16 2/15/20236,880,000 shares $138.43 million -7.7%N/A5.8 $20.12 1/31/20237,450,000 shares $166.88 million -0.9%N/A8.8 $22.40 1/15/20237,520,000 shares $152.81 million -10.3%N/A9.1 $20.32 12/30/20228,380,000 shares $176.23 million +3.1%N/A10 $21.03 12/15/20228,130,000 shares $150.41 million -1.2%N/A9.7 $18.50 11/30/20228,230,000 shares $165.67 million +5.9%N/A10.6 $20.13 11/15/20227,770,000 shares $167.13 million -1.2%N/A10.4 $21.51 10/31/20227,860,000 shares $170.40 million +23.0%13.0%10.9 $21.68 10/15/20226,390,000 shares $132.15 million -6.2%10.6%8.4 $20.68 9/30/20226,810,000 shares $167.80 million +3.0%11.3%10.3 $24.64 9/15/20226,610,000 shares $179.79 million -0.5%11.0%9.9 $27.20 8/31/20226,640,000 shares $177.69 million -10.2%11.1%9 $26.76 8/15/20227,390,000 shares $211.28 million +7.9%12.3%9.7 $28.59 7/31/20226,850,000 shares $161.25 million +2.4%11.5%7.9 $23.54 7/15/20226,690,000 shares $163.97 million -5.0%11.2%8.4 $24.51 6/30/20227,040,000 shares $170.58 million +6.2%11.8%8.6 $24.23 6/15/20226,630,000 shares $160.18 million -10.4%11.1%8 $24.16 5/31/20227,400,000 shares $172.49 million -12.6%12.4%8.9 $23.31 5/15/20228,470,000 shares $187.86 million +3.7%14.2%9.7 $22.18 4/30/20228,170,000 shares $205.31 million +14.1%13.8%10.5 $25.13 4/15/20227,160,000 shares $212.22 million +0.7%12.1%9.3 $29.64 3/31/20227,110,000 shares $183.22 million -6.5%12.0%9.8 $25.77 3/15/20227,600,000 shares $181.72 million +29.3%12.8%11.5 $23.91Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.👉 Unlock the ticker now and get it completely free. 2/28/20225,880,000 shares $160.29 million -1.7%10.0%9.1 $27.26 2/15/20225,980,000 shares $171.39 million +11.4%10.5%11 $28.66 1/31/20225,370,000 shares $147.68 million +8.5%9.3%10.6 $27.50 1/15/20224,950,000 shares $136.32 million -15.5%8.5%9.3 $27.54 12/31/20215,860,000 shares $181.89 million -6.4%N/A0 $31.04 12/15/20216,260,000 shares $182.48 million +0.6%10.8%11.6 $29.15 11/30/20216,220,000 shares $177.58 million +3.0%10.7%10.5 $28.55 11/15/20216,040,000 shares $177.39 million -1.2%10.4%9.7 $29.37 10/29/20216,110,000 shares $176.03 million +0.5%10.1%5 $28.81 10/15/20216,080,000 shares $148.96 million -6.9%10.2%5.1 $24.50 9/30/20216,530,000 shares $158.35 million -5.6%10.9%5.4 $24.25 9/15/20216,920,000 shares $162.83 million -3.1%11.5%5.4 $23.53 8/31/20217,140,000 shares $155.87 million +6.7%11.9%5.5 $21.83 8/13/20216,690,000 shares $103.36 million -1.6%11.2%4.9 $15.45 7/30/20216,800,000 shares $93.50 million +2.6%11.4%8.3 $13.75 7/15/20216,630,000 shares $90.83 million -1.5%11.1%8 $13.70 6/30/20216,730,000 shares $98.19 million +23.0%11.3%8.3 $14.59 6/15/20215,470,000 shares $81.67 million +19.4%9.2%7.5 $14.93 5/28/20214,580,000 shares $69.48 million -0.4%7.7%7 $15.17 TVTX Short Interest - Frequently Asked Questions What is Travere Therapeutics' current short interest? Short interest is the volume of Travere Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 14,216,705 shares of TVTX short. 16.00% of Travere Therapeutics' shares are currently sold short. Learn More on Travere Therapeutics' current short interest. What is a good short interest ratio for Travere Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TVTX shares currently have a short interest ratio of 7.2. Learn More on Travere Therapeutics's short interest ratio. What is a good short interest percentage for Travere Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.00% of Travere Therapeutics' floating shares are currently sold short. Is Travere Therapeutics' short interest increasing or decreasing? Travere Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 14,216,705 shares, an increase of 11.7% from the previous total of 12,725,544 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Travere Therapeutics' short interest compare to its competitors? 16.00% of Travere Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Travere Therapeutics: Ascendis Pharma A/S (7.57%), Regencell Bioscience Holdings Limited (0.16%), BridgeBio Pharma, Inc. (14.30%), Summit Therapeutics PLC (22.80%), Axsome Therapeutics, Inc. (6.73%), Dr. Reddy's Laboratories Ltd (1.92%), Arrowhead Pharmaceuticals, Inc. (9.53%), Elanco Animal Health Incorporated (4.93%), Cytokinetics, Incorporated (13.12%), Abivax SA Sponsored ADR (3.21%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($86.09 billion), Invesco QQQ ($39.89 billion), iShares Russell 2000 ETF ($26.13 billion), Western Digital Corporation ($12.66 billion), Salesforce Inc. ($12.29 billion), Sandisk Corporation ($11.87 billion), SPDR S&P Biotech ETF ($9.82 billion), Lumentum Holdings Inc. ($8.51 billion), iShares 20+ Year Treasury Bond ETF ($7.76 billion), and Bloom Energy Corporation ($7.40 billion). View all of the most shorted stocks. What does it mean to sell short Travere Therapeutics stock? Short selling TVTX is an investing strategy that aims to generate trading profit from Travere Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Travere Therapeutics? A short squeeze for Travere Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TVTX, which in turn drives the price of the stock up even further. How often is Travere Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TVTX, twice per month. The most recent reporting period available is April, 30 2026. What do TVTX's short interest metrics mean? Understanding short interest metrics can help you assess how traders are positioning around a stock like TVTX:Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity. More Short Interest Resources from MarketBeat Related Companies Ascendis Pharma A/S Short Interest Data Regencell Bioscience Short Interest Data BridgeBio Pharma Short Interest Data Summit Therapeutics Short Interest Data Axsome Therapeutics Short Interest Data Dr. Reddy's Laboratories Short Interest Data Arrowhead Pharmaceuticals Short Interest Data Elanco Animal Health Short Interest Data Cytokinetics Short Interest Data Abivax Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TVTX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
